Long-sought-after anti-cancer agent synthesized
February 1st, 2011 - 6:02 pm ICT by ANIWashington, Feb 1 (ANI): For the first time, Yale University scientists have synthesized a chemical compound, leading to the development of a new class of molecules that may target and destroy cancer stem cells.
A team at Yale, led by chemist Seth Herzon, managed to create the chemical called lomaiviticin aglycon, opening up new avenues of exploration into novel chemotherapies that could target cancer stem cells, thought to be the precursors to tumors in a number of different cancers including ovarian, brain, lung, prostate and leukemia.
Gil Mor of the Yale School of Medicine said that in addition to lomaiviticin aglycon, Herzon’s team also created smaller, similar molecules that have proven extremely effective in killing ovarian stem cells.
The scientists are particularly excited about lomaiviticin aglycon’s potential to kill ovarian cancer stem cells because the disease is notoriously resistant to Taxol and Carboplatin, two of the most common chemotherapy drugs.
“Ovarian cancer has a high rate of recurrence, and after using chemotherapy to fight the tumor the first time, you’re left with resistant tumor cells that tend to keep coming back. If you can kill the stem cells before they have the chance to form a tumor, the patient will have a much better chance of survival - and there aren’t many potential therapies out there that target cancer stem cells right now,” explained Mor.
The findings appeared in the Journal of the American Chemical Society. (ANI)
- New study shows evidence of stem cells' pivotal role in cancer - Dec 22, 2010
- Bioengineered protein may help fight leukemia - Feb 19, 2011
- Scientists make anti-cancer compounds - Feb 13, 2010
- How ovarian cancer resists chemotherapy - Mar 03, 2011
- New discovery may help in the fight against ovarian cancer - Feb 04, 2011
- Possible new treatment strategies for pancreatic cancer found - Mar 04, 2011
- 'Good cholesterol' nanoparticles may help fight cancer - Apr 02, 2011
- Gene makes ovarian cancer resistant to chemotherapy - Mar 03, 2011
- Study sheds light on blood stem cell, leukemia link - Aug 17, 2010
- Small molecule may deactivate enemy of cancer-fighting p53 - Dec 08, 2010
- Biophysicist attempts to block protein to prevent breast, prostate cancer - Apr 20, 2011
- Nanosponge drug treatment 3-5 times more effective than jabs - Jun 03, 2010
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- Blue light could be highly in potent platinum-based cancer treatment - Dec 10, 2010
- Small molecules 'could block cell proliferation in cancerous human tumor' - Apr 14, 2011
Tags: american chemical society, better chance, cancer agent, carboplatin, chemical compound, chemotherapies, chemotherapy drugs, journal of the american chemical society, new avenues, ovarian cancer, precursors, recurrence, school of medicine, stem cells, target, taxol, tumor cells, university scientists, yale school of medicine, yale university